The AGA’s Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics-Reference-Cited by-同舟云学术

The AGA’s Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics

Published:2017-03 Issue:4 Volume:152 Page:681-684
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Kelly Colleen R.,Kim Alison M.,Laine Loren,Wu Gary D.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference15 articles.

1. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial;Kelly;Ann Intern Med,2016

2. Duodenal infusion of donor feces for recurrent Clostridium difficile;van Nood;N Engl J Med,2013

3. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook;Kelly;Gastroenterology,2015

4. Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies;Kelly;Clin Gastroenterol Hepatol,2014

5. Food and Drug Administration (FDA). Public workshop: Fecal microbiota for transplantation. 2013; Available: www.fda.gov/biologicsbloodvaccines/newsevents/workshopsmeetingsconferences/ucm341643.htm. Accessed September 26, 2016.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cultured fecal microbial community and its impact as fecal microbiota transplantation treatment in mice gut inflammation;Applied Microbiology and Biotechnology;2024-09-13

2. Correlation of non-alcoholic fatty liver disease and gut microflora: clinical reports and treatment options;Egyptian Liver Journal;2024-04-01

3. Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future;Clinical Infectious Diseases;2023-12-01

4. Eating disorders: are gut microbiota to blame?;Trends in Molecular Medicine;2023-11

5. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent Clostridioides difficile infection;Expert Review of Anti-infective Therapy;2023-02-09